Trial Profile
A Retrospective Long Term Response to First-Line Pazopanib therapy in Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 03 Aug 2018 New trial record
- 01 Aug 2018 Results published in the Anticancer Research